Inhibikase Therapeutics, Inc. (IKT) stock
Close on Nov 11, 2026Market cap $227.44MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $227.44M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.20
- Dividend yield
- –
- Free cash flow yield
- -21.71%
Fundamentals
- Net income
- -$69.17M
- EPS, diluted
- -$0.41
- Free cash flow
- -$49.37M
- Book value per share
- $0.96
- Diluted shares
- 197M
Trading
- Next earnings
- Mar 25, 2027 (estimated, during market hours)
- Previous close
- $1.55
- Open
- $1.56
- Day's range
- $1.55 – $1.66
- Volume
- 413,431
- Average volume (20 days)
- 613,447
- Index membership
- Russell 2000 (since Jun 2025)
- Beta (5 years)
- 1.14
- 52-week range
- $1.40 – $2.61
- RSI (14 days)
- 46.8
- Volatility (1 year)
- 63.5%
- Relative volume
- 0.61×
- WACC
- 10.6%
On 1 of our idea list: More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | IKT | S&P 500 | Difference | IKT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -17.3% | -2.4% | −14.8 pts | ||
| 3 months | -33.5% | -1.2% | −32.3 pts | ||
| Year to date | -20.5% | +12.3% | −32.8 pts | ||
| 1 year | -0.6% | +12.4% | −13.1 pts | ||
| 3 years | +63.0% | +78.8% | −15.8 pts | +17.7% | +21.4% |
| 5 years | -86.6% | +75.2% | −161.8 pts | -33.1% | +11.9% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Inhibikase Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Update
- News
About Inhibikase Therapeutics
Biological Products, (No Diagnostic Substances)
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company that develops therapeutics designed to modify the course of cardiopulmonary diseases. The company focuses primarily on treatments for pulmonary arterial hypertension, an orphan disease marked by elevated pulmonary vascular resistance and vascular remodeling. Its primary product candidate is IKT-001, an oral prodrug of imatinib designed to minimize gastrointestinal adverse effects by exhibiting lower inhibitory activity at target tyrosine kinases such as c-Kit. As a clinical-stage entity, the company does not currently sell commercial products to end customers, but its pipeline targets patients suffering from pulmonary arterial hypertension.
Company profile, executives and historyInhibikase Therapeutics stock: common questions
What is Inhibikase Therapeutics's stock price?
IKT closed at $1.63 on Nov 11, 2026, up 5.16% on the day. Over the past 52 weeks it traded between $1.40 and $2.61.
What is Inhibikase Therapeutics's market cap?
Inhibikase Therapeutics was worth $227.44M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is IKT's P/E ratio?
Inhibikase Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.41), so it has no meaningful P/E ratio.
Does Inhibikase Therapeutics pay a dividend?
No. Inhibikase Therapeutics has not paid a cash dividend over the last twelve months.
When does Inhibikase Therapeutics report earnings next?
Inhibikase Therapeutics is expected to report Q4 FY2026 results on Mar 25, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has IKT stock performed over the past year?
Including dividends, IKT returned -0.6% over the past year, against +12.4% for the S&P 500.
How many IKT shares are sold short?
19M shares were sold short at the latest FINRA report, 16.47% of the float, or 28.6 days of average trading volume.
Who are Inhibikase Therapeutics's competitors?
Companies most similar to Inhibikase Therapeutics by business, industry and size include GOSS, TECX, TVRD, KLRS, SLDB.
See a number that looks wrong?